Therapy Areas: Central Nervous System
Saniona plans development of preclinical candidate SAN903 to phase 1 clinical study in 18 months
23 July 2019 -

Saniona AB (STO:SANION), a research and development company focused on drugs for diseases of the central nervous system and eating disorders, announced on Monday the selection of a new development candidate, SAN903, for preclinical development, which can enter clinical phase 1 in only 18 months.

Based on work done to date, Saniona said it has elected to focus SAN903 initially on the treatment of Crohn's disease and colitis.

According to the company, SAN903, which is generated from the company's advanced ion channel platform, is a first-in-class product and, Saniona believes it has the potential to transform the treatment paradigm for severe autoimmune diseases, including Crohn's disease and colitis.

With SAN903, Saniona has identified a novel proprietary IK channel inhibitor that effectively dampens gut inflammation and can be used for the treatment of inflammatory bowel diseases (IBD), like Crohn`s disease and ulcerative colitis. The drug will likely be the first ion channel modulator for IBD.

In addition, SAN903 also has potential in certain rare blood diseases, where Saniona may obtain an orphan designation and develop the product all the way to the market.

This preclinical development of SAN903 will encompass scale-up of the manufacturing process, GMP production and various toxicology studies, which will form the basis for a regulatory application to initiate first-in-man clinical trials.

Saniona added that it is concurrently working with its development partners to initiate phase 1 clinical trials early 2021.

Login
Username:

Password: